Ocugen, Inc.
Close on Oct 19, 2026
- Market cap
- $266.64M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $1.49M | $-0.07 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 4, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 4, 2026 | During market hours | -$193.00K | $-0.06 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $1.75M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 1, 2025 | During market hours | $1.37M | $-0.05 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 9, 2025 | During market hours | $1.48M | $-0.05 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 5, 2025 | Before market open | $764.00K | $-0.05 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 8, 2024 | During market hours | $1.14M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | Before market open | – | – | – |
Press releases
Announcements Ocugen filed with the SEC
Dedicated to Bringing Game-Changing Gene
Regulation FD disclosure · EX-99.1 to Form 8-K
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Dedicated to Bringing Game-Changing Gene
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ocugen Provides Business Update with Second
Results of operations · EX-99.1 to Form 8-K
Dedicated to Bringing Game-Changing Gene
Results of operations · EX-99.2 to Form 8-K
Ocugen, Inc. Announces Binding Term Sheet with Roots
Other events · EX-99.1 to Form 8-K
Ocugen, Inc. Announces Closing for $130.0 Million
New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Ocugen Provides Business Update with First
Results of operations · Other events · EX-99.1 to Form 8-K
Courageous Innovation Dedicated to Bringing Game - Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally
Results of operations · Other events · EX-99.2 to Form 8-K
Ocugen, Inc. Announces Pricing of $115 Million
Results of operations · Other events · EX-99.3 to Form 8-K
Excerpts from Preliminary Offering Memorandum
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Courageous Innovation Dedicated to Bringing Game-Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally
Regulation FD disclosure · EX-99.1 to Form 8-K
Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular
Regulation FD disclosure · EX-99.1 to Form 8-K
Courageous Innovation Topline Data for Phase 2 ArMaDa Trial A Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy (late - stage dry AMD)
Regulation FD disclosure · EX-99.2 to Form 8-K
Courageous Innovation Dedicated to Bringing Game - Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally
Regulation FD disclosure · EX-99.3 to Form 8-K
THE COURT OF CHANCERY OF THE STATE OF DELAWARE
Other events · EX-99.1 to Form 8-K
Ocugen Provides Business Update with Fourth
Results of operations · EX-99.1 to Form 8-K
Courageous Innovation Dedicated to Bringing Game - Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally
Results of operations · EX-99.2 to Form 8-K
Ocugen, Inc. Announces Closing of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of
Material agreement · Other events · EX-99.1 to Form 8-K
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy
Other events · EX-99.1 to Form 8-K
Dedicated to Bringing Game-Changing Gene
Other events · EX-99.2 to Form 8-K
Ocugen Provides Business Update with Third Quarter
Results of operations · EX-99.1 to Form 8-K
Ocugen, Inc. Announces $20 Million Registered
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Ocugen Provides Business Update with Second
Results of operations · EX-99.1 to Form 8-K
Carisma Therapeutics and OrthoCellix Enter into
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Visual Field 0 10 20 30 40 50 60 70 80 P ro p o rt io n o f R e s p o n d e rs 75% 6/8
Other events · EX-99.1 to Form 8-K
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License
Shareholder vote results · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
× μ • o • •
Results of operations · EX-99.2 to Form 8-K
% ± • • •
Regulation FD disclosure · EX-99.1 to Form 8-K
12 × μ • o • •
Other events · EX-99.1 to Form 8-K
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
× μ • o • •
Results of operations · EX-99.2 to Form 8-K
13 × μ • o • •
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K